Drug Information

Drug General Information
Drug ID
D0L9PA
Former ID
DIB014720
Drug Name
X-396
Synonyms
ALK inhibitors (cancer); X-276; X-353; X-376; X-396; ALK inhibitors (cancer), Xcovery; Anaplastic lymphoma kinase inhibitors (cancer), Xcovery
Drug Type
Small molecular drug
Indication Advanced solid tumor [ICD9: 140-199; ICD10:C00-C75, C7A, C7B] Phase 1/2 [523953]
Company
Xcovery
Formula
C25H25Cl2FN6O3
Canonical SMILES
CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=CC(=NN=C2N)C(=O)NC3=CC=C(C=<br />C3)C(=O)N4CCN(CC4)C
InChI
1S/C25H25Cl2FN6O3/c1-14(21-17(26)7-8-18(28)22(21)27)37-20-13-19(31-32-23(20)29)24(35)30-16-5-3-15(4-6-16)25(36)34-11-9-33(2)10-12-34/h3-8,13-14H,9-12H2,1-2H3,(H2,29,32)(H,30,35)/t14-/m1/s1
InChIKey
ONPGOSVDVDPBCY-CQSZACIVSA-N
PubChem Compound ID
56960447
PubChem Substance ID
135674224, 136920379, 172650910, 174500821, 175445211, 198965485, 240090121
Target and Pathway
Target(s) ALK tyrosine kinase receptor Target Info Inhibitor [551778]
KEGG Pathway Non-small cell lung cancer
WikiPathways Differentiation Pathway
References
Ref 523953ClinicalTrials.gov (NCT01625234) Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 551778Clinical pipeline report, company report or official report of Xcovery.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.